Shares Offered in Nanomedicine Platform

BIND Therapeutics has proposed that shares in the company be offered publicly.

Credit Suisse and Cowen and Company LLC are working as book-running managers for the public offering, registration for which has already been filed to the US Securities and Exchange Commission. However, the exact price and number of shares to be made available has yet to be decided.

The company BIND Therapeutics is a clinical-stage nanomedicine platform working on the development of Accurins, which is used in treatments such as cancer chemotherapy.

Its leading drug candidate BIND-014 is currently in the second phase of clinical trials for treating non-small cell lung cancer and metastatic castrate resistant prostate cancer.

Statistics show that less than half of patients with non-small cell lung cancer survive for at least 5 years after diagnosis.

Prostate cancer is most frequently diagnosed malignancy in men and, in the UK, 22% of cases are estimated to have advanced to metastatic disease.